



14 January 2016

Prof Philip Stricker  
Department of Urology  
Suite 1001 St Vincent's Clinic  
408 Victoria Street  
Darlinghurst NSW 2010

A facility of St Vincent's  
& Mater Health Sydney

St Vincent's Hospital Sydney Ltd  
ABN 77 054 038 872  
390 Victoria Street  
Darlinghurst NSW 2010  
Australia

T + 61 2 8382 1111  
F + 61 2 9332 4142  
www.stvincents.com.au

Dear Philip,

**SVH File Number: 15/262**

**Project Title: The MAGNIFI Trial: Metastasis assessment with Gallium-68 PSMA and Nanoparticle Imaging Fusion International**

**Short Title: MAGNIFI Trial**

**HREC Reference Number: HREC/15/SVH/402**

Thank you for your letter, dated **17 December 2015**, responding to issues raised regarding the above project, which was first considered by the St Vincent's Hospital HREC at its meeting held on **12 November 2015**. St Vincent's Hospital HREC (EC00140) has been accredited by NSW Ministry of Health as a Lead HREC under the model for single ethical and scientific review and Certified by the NHMRC under the National Certification Scheme. This lead HREC is constituted and operates in accordance with the National Health and Medical Research Council's *National Statement on Ethical Conduct in Human Research* and the *CPMP/ICH Note for Guidance on Good Clinical Practice*. No HREC members with a conflict of interest were present for review of this project.

This project meets the requirements of the National Statement on Ethical Conduct in Human Research. I am pleased to advise that the Committee at an Executive meeting on **12 January 2016** has granted ethical and scientific approval of the above **multi centre** project.

**You are reminded that this letter constitutes *ETHICAL* and *SCIENTIFIC* approval only. You must not commence this research project at a site until a completed Site Specific Assessment Form/Access Request and associated documentation have been submitted to the site Research Governance Officer and authorised. A copy of this letter must be forwarded to all site investigators for submission to the relevant Research Governance Officer.**

The project is approved to be conducted at

- **St Vincent's Hospital, Sydney**
- **Garvan Institute**
- **St Vincent's Prostate Cancer Centre (St Vincent's Clinic private rooms).**

**If a new site(s) is to be added please inform the HREC in writing and submit a Site Specific Assessment Form (SSA) to the Research Governance Officer at the new site.**

The following documentation has been reviewed and approved by the HREC:

- Protocol, Version 1.1, dated 29 September 2015
- Participant Information Sheet and Consent form, Version 1.2, dated 1 October 2015
- Magnifi Trial: Eligibility Check List, Version 1.0, dated 1 October 2015
- Magnifi Trial: Initial Assessment Form (Form A), Version 1.0, dated 1 October 2015
- Magnifi Trial: 68Ga PSMA Reporting form (Form B), Version 1.0, dated 1 October 2015
- Magnifi Trial: Nano MRL Reporting Form (Form C), Version 1.0, dated 1 October 2015
- Magnifi Trial: Follow up Assessment Form (Form D), Version 1.0, dated 1 October 2015
- EPIC survey, Version EPIC\_AUA\_SF12-12-2015, dated 20 May 2015

The following documentation was noted by the HREC:

- Combindex (ferumoxtran-10, NDA 21-115) Oncology Drugs Advisory Committee Briefing Document, 28 January 2015

- Summary of the evaluation of the EMEA CHMP registration process, concerning the value and safety of Sinerem/Combixidex (ferumoxtran-10)

**Copies of site authorisation letters must be forwarded to St Vincent's Hospital Research Office before the site is entered into the TGA CTN Scheme online form.**

The National Ethics Application Form (NEAF) document reviewed by the HREC was NEAF **AU/1/A832214**

Please note the following conditions of approval:

- HREC approval is valid for **5 years** from the date of the HREC Executive Committee meeting and expires on **12 January 2021**. The Co-ordinating Investigator is required to notify the HREC 6 months prior to this date if the project is expected to extend beyond the original approval date at which time the HREC will advise of the requirements for ongoing approval of the study.
- The Co-ordinating Investigator will provide an annual progress report beginning in **January 2017**, to the HREC as well as a final study report at the completion of the project in the specified format.
- The Co-ordinating Investigator will immediately report anything which might warrant review of ethical approval of the project in the specified format, including unforeseen events that might affect continued ethical acceptability of the project and any complaints made by study participants regarding the conduct of the study.
- Proposed changes to the research protocol, conduct of the research, or length of HREC approval will be provided to the HREC for review, in the specified format.
- The HREC will be notified, giving reasons, if the project is discontinued before the expected date of completion.
- Investigators holding an academic appointment (including conjoint appointments) and students undertaking a project as part of a University course may also be required to notify the relevant University HREC of the project. Investigators and students are advised to contact the relevant HREC to seek advice regarding their requirements.

Please note it is the responsibility of the sponsor or the co-ordinating investigator of the project to register this study on a publicly available online registry (eg. Australian Clinical Trial Registry <http://www.anzctr.org.au/>).

Please note that only an electronic copy of this letter will be provided, if you require the original signed letter please contact the Research Office and we will be happy to provide this.

Should you have any queries regarding this project please contact the Research Office, Tel: 8382-2075, email [SVHS.Research@svha.org.au](mailto:SVHS.Research@svha.org.au). The HREC Terms of Reference, Standard Operating Procedures, *National Statement on Ethical Conduct in Human Research* (2007) and the *CPMP/ICH Note for Guidance on Good Clinical Practice* and standard forms are available on the Research Office website: <https://svhs.org.au/home/research-education/research-office>

Please quote **SVH File Number: 15/262** in all correspondence.

The HREC wishes you every success in your research.

Yours sincerely,



**Sarah Charlton**  
**HREC Executive Officer**  
**St Vincent's Hospital Research Office**  
**Level 6, de Lacy Building**

cc. Pim van Leeuwen, Quoc Nguyen

TRIM REF: D/2016/1128